Glenmark Pharmarolls outlow-cost drug for diabetes

Glenmark Pharmarolls outlow-cost drug for diabetes
Highlights

Glenmark Pharmaceuticals, a drug major on Thursday launched a patent protected sodium glucose co-transporter (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.

Hyderabad: Glenmark Pharmaceuticals, a drug major on Thursday launched a patent protected sodium glucose co-transporter (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.

The drug is indicated in the treatment of type-2 diabetes mellitus in adults.

The drug was launched under brand names Remo and Remozen, at a price of Rs 12.50 per tablet.

The new diabetic drug, Remogliflozin, was discovered and developed by Japanese firm Kissei Pharmaceutical Co Ltd and later developed by GlaxoSmithKline plc and Glenmark collaborator BHV Pharma, a wholly owned subsidiary of North Carolina USA-based Avolynt, Inc.

The drug company expects 12 to 14 per cent growth in its India revenues during the current fiscal, Sujesh Vasudevan, President, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals said.

Show Full Article
Download The Hans India Android App or iOS App for the Latest update on your phone.
More Stories


Top